APA (7th ed.) Citation

S, R., A, C., S, D., M, S., I, S., L, P., . . . PG, R. (2021). Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. American journal of hematology, 96(9), 1120. https://doi.org/10.1002/ajh.26261

Chicago Style (17th ed.) Citation

S, Richard, et al. "Selinexor, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Previously Treated Multiple Myeloma: Outcomes by Cytogenetic Risk." American Journal of Hematology 96, no. 9 (2021): 1120. https://doi.org/10.1002/ajh.26261.

MLA (9th ed.) Citation

S, Richard, et al. "Selinexor, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Previously Treated Multiple Myeloma: Outcomes by Cytogenetic Risk." American Journal of Hematology, vol. 96, no. 9, 2021, p. 1120, https://doi.org/10.1002/ajh.26261.